Group LeaderLocation and ContactMembersHistory of the GroupLines of ResearchNotable PublicationsProjectsPhD ThesesClinical TrialsNews
Dr Cristina Martínez

Cristina Martínez González

  • Cristina Martínez González obtained her Bachelor’s degree in Medicine at the Universidad de Oviedo in 1979. She became a consultant in Pulmonology in 1984, having completed the Spanish Medical Residency Programme (MIR) at the Instituto Nacional de Silicosis (National Institute for Silicosis, INS) between 1980 and 1984. She received her PhD in Medicine from the Universidad de Oviedo in 1995, and became a consultant in Occupational Medicine in 2004. She completed the “Clinical Leadership in Pulmonology through Five Books”, run by the Fundación Josep Laporte, SEPAR (Spanish Society of Pulmonology and Thoracic Surgery) and the Institut de Estudis de la Salut (Health Studies Institute) in 2009.
  • She has been an Associate Lecturer in the Faculty of Medicine at the Universidad de Oviedo since 2010 and is accredited by ANECA as a Lecturer (Profesora Contratada Doctora) and Assistant Lecturer (Profesora Ayudante Doctora). She has been Vice-President of the Comisión Nacional de Neumología (National Pulmonology Commission) since 2014.
  • Clinical practice as a Specialist Health Professional (F.E.A.) and Section Head in the Pulmonology Department of the INS and the Hospital Universitario Central de Asturias since 1988.
  • Member of the editorial board of Archivos Bronconeumología. Member of the Expert Committee of the Ministry of Health, Social Services and Equality’s Observatorio de Salud y Cambio Climático (Health and Climate Change Observatory) since September 2001.
  • Research projects: PI on four national projects and AI on nine national projects.
  • Author of over 60 scientific publications in books and journals listed on JCR, Pubmed, WOS and Scopus; H-index of 17, i10-index of 29. 30 invited talks and over 50 presentations in national and international conferences.
  • Panel member on the Technical Assessment Commission for Chronic, Inflammatory, Nephrological and Respiratory Diseases in Health Research Projects for the Acción Estratégica en Salud (Strategic Action in Health Research) funding round 2017, 2018 and 2019.
  • Member of the assessment group identifying good practice in the Spanish National Health System.
Group Leader until December 2019
Professor Pere Casan Clarà

Pere Casán Clará

  • Research results: H-index 30; 145 publications in journals ranked by JCR and listed on Pubmed, WOS and Scopus, the most important of which have been cited 450 (2000), 284 (2002), 223 (2004), and 176 (2003) times. 58 presentations at national and international scientific conferences.
  • Research projects: PI on four national projects and six regional projects. Researcher on 12 national and regional projects.
  • Results transfer: Two products equivalent to registered models. PI in three private-sector partnerships for technology transfer . 57 courses delivered to health professionals.
  • Mobility: Guest Researcher at the Department of Medicine, Health Science Centre, MacMaster University, Hamilton, Ontario (Canada).
  • Other Research Experience: Assessor for ANEP (National Agency for Assessment and Prospective Studies) and ANECA (National Agency for Quality Assessment and Accreditation). Member of the Expert Commission for the Spanish Ministry of Education and Culture. Scientific Committee member for five international conferences. Reviewer for seven JCR-ranked journals and three international conferences. Five research periods (of six years).
  • Teaching responsibilities as University Professor of Pulmonology:
    Teaching on Medicine courses since 1987. Supervision of 10 PhD theses and 12 PhD projects.
    This teaching work has been performed in his capacity as Director of the Master’s degree in Advances in Diagnostics and Treatment of Respiratory Tract Diseases at the Universidad Católica San Antonio de Murcia.

Servicio de Neumología

Hospital Universitario Central de Asturias.

Avenida Hospital Universitario s/n. 33011, Oviedo, Spain.

Name Organisation Activity Euraxess classification
Arias Guillén, Miguel SESPA Research/Clinical/Teaching R3
Ariza Prota, Miguel Angel SESPA Research/Clinical/Teaching R2
Bedate Díaz, Pedro SESPA Research/Clinical/Teaching R2
Fernández Álvarez, Ramón SESPA Research/Clinical/Teaching R2
García Clemente, Marta SESPA Research/Clinical/Teaching R2
Iscar Urrutia, Marta SESPA Research/Clinical/Teaching R2
López González, Francisco Julián SESPA Research/Clinical/Teaching R2
Martínez González, Cristina SESPA Research/Clinical/Teaching R3
Pando Sandoval, Ana SESPA Research/Clinical R2
Rodríguez Jerez, Francisco José SESPA Research/Clinical/Teaching R2
Rubinos Cuadrado, Gemma SESPA Research/Clinical/Teaching R2
Vázquez López, María José SESPA Research/Clinical/Teaching R2

How the Group was Formed

It was the interest of the members of HUCA’s Lung Clinical Management Division in continuing to expand our knowledge about diseases of the airways that led to the creation of the Respiratory Disease Research Group.

Current and Future Priorities

Interstitial Lung Diseases : The introduction of the first effective treatments for interstitial lung diseases three years ago (most significantly, for the most common of these diseases with the worst prognosis, idiopathic pulmonary fibrosis) and the costs associated with them created a need for interdisciplinary collaboration between HUCA specialists (in radiology, pathological anatomy, microbiology, rheumatology, etc.), which led to the creation of a specific group to evaluate, prescribe and administer said treatments. This group also performs some basic research on the drugs’ mechanisms of action and their possible indications for silicosis: an extremely relevant disease in Asturias. In the last few decades, the advance in genotyping techniques has led to the identification of a large number of sporadic and familial genetic variants in patients with interstitial pulmonary fibrosis. These studies have enabled us to develop a broader understanding of the pathogenesis of pulmonary fibrosis. Susceptibility to idiopathic pulmonary fibrosis seems to involve a combination of polymorphisms related to epithelial cell lesion and abnormal repair of the lesions. Surfactant Protein C Mutations: One of the first genetic associations identified by researchers was a mutation in SFTPC – a gene which codes surfactant protein C – a highly hydrophobic protein that is essential to postnatal lung function and homeostasis. Telomerase Mutations: Telomerase is an enzyme that is responsible for the addition of deoxyribonucleotides to the ends of the telomeres, but this addition is controlled by a sequence of ribonucleotides or RNA, meaning that it can be described as a reverse transcriptase with special characteristics.

  • Occupational Diseases.
  • Diffuse Interstitial Lung Disease - Idiopathic Pulmonary Fibrosis.
  • Chronic Obstructive Pulmonary Disease.
  • Obstructive Sleep Apnea.
  • Tuberculosis.
  1. AUTHORS: Ruano-Ravina A, Pérez-Ríos M, Casàn-Clará P, Provencio-Pulla M.
    TITLE: Low-dose CT for lung cancer screening.
    Lancet Oncol. 2018 Mar;19(3):e131-e132. doi: 10.1016/S1470-2045(18)30121-9.
    Impact factor: 36.418.
    Quartile: Q1
  2. AUTHORS: Arias-Guillén M, Sánchez Menéndez MM, Alperi M, Riestra-Menéndez S, González Budiño MT, García-Clemente MM, Martínez-González S, Enríquez AI, Alonso-Arias R, Palacios Gutiérrez JJ, Santibáñez M, Coto-Segura P, Camblor PM, García-Alfonso L, Morante I, Escalante P.
    TITLE: High rates of tuberculin skin test positivity due to methotrexate therapy: False positive results?
    Semin Arthritis Rheum. 2018 Mar 29. pii: S0049-0172(17)30652-2. doi: 10.1016/j.semarthrit.2018.03.018.
    Impact factor: 4.356.
    Quartile: Q1
  3. AUTHORS: Martínez-González C, Casanova C, de-Torres JP, Marín JM, de Lucas P, Fuster A, Cosío BG, Calle M, Peces-Barba G, Solanes I, Agüero R, Feu-Collado N, Alfageme I, Romero Plaza A, Balcells E, de Diego A, Marín Royo M, Moreno A, Llunell Casanovas A, Galdiz JB, Golpe R, Lacárcel Bautista C, Cabrera C, Marin A, Soriano JB, Lopez-Campos JL; CHAIN Study Investigators.
    TITLE: Changes and Clinical Consequences of Smoking Cessation in Patients With COPD: A Prospective Analysis From the CHAIN Cohort.
    Chest. 2018 Feb 22. pii: S0012-3692(18)30265-4. doi: 10.1016/j.chest.2018.02.007. (Epub ahead of print)
    Impact factor: 7.652.
    Quartile: Q1
  4. AUTHORS: Kessler R, Casan-Clara P, Koehler D, Tognella S, Viejo JL, Dal Negro RW, Díaz-Lobato S, Reissig K, Rodríguez González-Moro JM, Devouassoux G, Chavaillon JM, Botrus P, Arnal JM, Ancochea J, Bergeron-Lafaurie A, De Abajo C, Randerath WJ, Bastian A, Cornelissen CG, Nilius G, Texereau JB, Bourbeau J.
    TITLE: COMET: a multicomponent home-based disease-management programme versus routine care in severe COPD.
    Eur Respir J. 2018 Jan 11;51(1). pii: 1701612. doi: 10.1183/13993003.01612-2017. Print 2018 Jan.
    Impact factor: 12.242.
    Quartile: Q1
  5. AUTHORS: Casanova C, Celli BR, de-Torres JP, Martínez-Gonzalez C, Cosio BG, Pinto-Plata V, de Lucas-Ramos P, Divo M, Fuster A, Peces-Barba G, Calle-Rubio M, Solanes I, Aguero R, Feu-Collado N, Alfageme I, De Diego A, Romero A, Balcells E, Llunell A, Galdiz JB, Marin M, Moreno A, Cabrera C, Golpe R, Lacarcel C, Soriano JB, López-Campos JL, Soler-Cataluña JJ, Marin JM.
    TITLE: Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD.
    Eur Respir J. 2017 Nov 22;50(5). pii: 1701162.
    Impact factor: 6.44.
    Quartile: Q1
  6. AUTHORS: Fernández Alvarez R, Rabec C, Rubinos Cuadrado G, Cascon Hernandez JA, Rodriguez P, Georges M, Casan P.
    TITLE: Monitoring Noninvasive Ventilation in Patients with Obesity Hypoventilation Syndrome: Comparison between Ventilator Built-in Software and Respiratory Polygraphy.
    Respiration. 2017;93(3):162-169. doi: 10.1159/000454954
    Impact factor: 2.772.
    Quartile: Q1
  7. AUTHORS: Ruano-Ravina A, Provencio-Pulla M, Casan Clarà P.
    TITLE: Lung Cancer Screening With Low-Dose Computed Tomography is not a Question of Logistics.
    Arch Bronconeumol. 2017 Oct;53(10):593-5
    Impact factor: 2.633.
    Quartile: Q2
Principal Investigator Title Funding Body Duration Amount
Cristina Martínez González Prevalence of respiratory disorders during sleep in patients with COPD SEPAR - Fundación Respira January 2015December 2016
Juan Miguel Barros Dios The molecular genetic profile of DNA repair markers (BER and NER) and the biological risk of lung cancer created by residential radon exposure: a multicentre case-control study Instituto de Salud Carlos III, PI 13/01765 January 2014 - December 2016 €128,683.50
Juan Bautista Galdiz Iturri Respiratory rehabilitation in patients with chronic respiratory diseases. Code: Telerehab SEPAR´14 and Instituto de Salud Carlos III January 2014 - December 2016 €1,134,765
Cristina Martínez González Longitudinal biomarker patterns and evolution of chronic obstructive pulmonary disease Instituto de Salud Carlos III. PI: 16/01506 January 2015 - December 2017 €108,295
Pere Casan Clarà Deposition of drugs and inhaled particles in the lungs: new applications using the computational fluid dynamics modelling technique FICYT (Foundation for the Promotion of Applied Scientific Research and Technology in Asturias); Chiesi November 2013 - November 2015 €50,000
Pere Casan Clarà Biomedical research to further smoking cessation Astra-Zéneca Farmaceútica Spain January 2013 - December 2013 €12,000
PhD Student Supervisor Title Year
Miguel Arias Guillén Pere Casan Clarà The performance of diagnostic tests to detect latent infectious tuberculosis in patients with an altered immune response. 2017
Marta Iscar Urrutia Marta María García Clemente Lung function at rest and under physiological stress in adult patients diagnosed with cystic fibrosis. 2015
Ana Fernández Tena Pere Casan Clarà Clinical Applications of Fluid Dynamics models in respiratory disease. 2014
Guillermo López-Arranz Monge Cristina Martínez González
Alberto Sicilia Felechosa
Chronic periodontitis (CP) as a risk factor affecting the severity of COPD: its association with the exacerbation and readmission rate. 2016
Francisco Julián López González Cristina Martínez González Markers of lung disease in workers exposed to silica. 2016
Title Sponsor Year
MICP-196. A Phase 2a, Double Blind, Placebo Controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects with Moderate to Severe COPD and Sputum Eosinophilia. Astra-Zéneca 2011 - 2013
GS-US-322-0207. A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER). Gilead 2013 - 2016
CTT116855. A Phase III, 52 Week, Randomised, Double-Blind, 3-Arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination Fluticasone Furoate/Umeclidinium/Vilanterol, with the Fixed Dose Dual Combinations of Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol, all Administered Once-Daily in the Morning via a Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease. Glaxo SmithKline 2015 - 2016
D3250C00017. A Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma (SIROCCO). Astra-Zéneca 2015 - 2016
DPMCF-303. Long Term Administration of Inhaled Mannitol in Cystic Fibrosis: a Safety and Efficacy Trial in Adult Cystic Fibrosis Subjects. Pharmacxis 2015
199.247. An Open-Label Extension Trial of the Long Term Safety of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Boheringer Ingelheim 2017
EPISCAN II. An Observational, Epidemiological, Cross-Sectional, National Study on the Prevalence of COPD in the Spanish Population. Glaxo Smith-Kline 2017
ML 39120 (AIRE). Observational Study t o Determine the Profile of Patients with Silicosis or Lung Disease Originating in Exposure to Silica at the Time of Diagnosis and the Subsequent Clinical Course. Roche Farma 2017